Harmen Beurmanjer

168 Supplements Patients in addiction care using GHB (Continued) Reference Aim Study design Methods Dijkstra et al., 2017; Jong, de et al., 2012; Kamal et al., 2016; Kamal et al., 2017; Weert, de – Oene, van et al., 2013 To explore the feasibility, effectiveness and safety of GHB detoxification by titration and tapering. Furthermore, to describe the clinical features of patients. Observational multicentre study between February 2011 - December 2012 N=229, 274 admissions (Dijkstra et al., 2017; Weert, de – Oene, van et al., 2013); N=23 (Jong, de et al., 2012); N=95 (Kamal et al, 2016); N=98 (Kamal et al, 2017). GHB dependent inpatients for detoxification in the Netherlands. Durgahee et al., 2014 To describe the patient characteristics, pattern of use, related problems and comorbidity. Retrospective database study between 2008- 2013. N=27, patients with primary GBL/GHB misuse representing to the Substance Misuse Service in Brighton and Hove (UK). Maxwell & Spence et al., 2005 To examine characteristics of individuals admitted to treatment for primary, secondary, or tertiary problems with club drugs. Retrospective database study (Texas Commission on Alcohol and Drug Abuse (TCADA) between 1988-2003 (GHB was added in 1997 to the system). N (GHB)=45, individuals admitted to treatment for primary, secondary, or tertiary problems with club drugs in publicly funded treatment in Texas (United States). Noorden, van et al., 2017 To assess treatment consumption and re- enrollment among patients with GHB dependence comparison with other addictions. Cohort study (LADIS database) of first treatment between 2008-2011 and consecutive treatments until 2013. N (total)=71,679; N (GHB)=596. In- and out-patients with alcohol, drug and/or behavioural addictions with first treatment episode in the Netherlands.